Drug combination outperforms chemotherapy in acute myeloid leukemia trial
A US clinical trial found a drug mix extended disease control and reduced hospital stays for acute myeloid leukemia patients.
Key Takeaways
AIA clinical trial in the United States has shown that a combination of drugs prolonged disease control and reduced hospital stays for patients with acute myeloid leukemia.
The study found that the combination of azacitidine and venetoclax outperformed traditional chemotherapy and may be more effective for some patients with acute myeloid leukemia, according to Asharq.
The trial, conducted by the Mass General Brigham Cancer Center in Massachusetts, revealed that patients receiving the azacitidine and venetoclax combination went more than twice as long before treatment failure, cancer recurrence, or disease progression compared to those who received intensive chemotherapy.
The benefits extended beyond cancer control, as patients in the less intensive treatment group also experienced lower rates of severe infections and bleeding complications.